ALK will invest to complete the remaining clinical development, secure registrations, build market access and gather evidence for the tablets' use in asthma, children and adolescents. In particular, the house dust mite SLIT-tablet is key to expanding the use of AIT for allergy and asthma – something that is already happening in Europe.

Key initiatives are: Clinical studies to complete the portfolio for all relevant ages, plus US post-approval commitments, and expanded tablet commercialisation.

The updated strategy – which builds upon ALK's successful European business and recent investments in North America – places succeeding with the tablet portfolio at its core, and has four key components: 1) Establish and succeed in North America; 2) Complete the tablet portfolio for all relevant ages; 3) Patient engagement systems and adjacent business; and 4) Optimise and reallocate ALK's resources.